CPDC https://validator.w3.org/feed/docs/rss2.html Accueil Home L’équipe Contact Us Team Contactez-nous Partner With Us News Création d’entreprise About Us Company Creation Opportunité D’emploi Career Opportunities CPDC lance Cadena Research, une ORC préclinique spécialisée dans les produits radiopharmaceutiques CPDC Launches Cadena Research, a Radiopharmaceutical Preclinical CRO Cadena Research Cadena Research CPDC lance Cadena Research, une ORC préclinique spécialisée dans les produits radiopharmaceutiques CQDM CQDM L2M Discover Radiopharma Board Call for Ideas: New Canadian Approaches in Radiopharmaceuticals Partenaires PSMA-1007 PSMA-1007 Investissements récents Recent Investments Nouvelles Conseil CMIE CMIE A propos de nous GMP Services Services BPF Partenaire avec nous CPDC Announces Seed Investment in Radiosyn Ltd. Our Focus Our Partners 1st Annual CMIE-CNIC Symposium on Medical Isotopes a Resounding Success in Vancouver – CMIE CPDC Celebrates Founder John Valliant and His Sixteen-Year Commitment to CPDC CPDC Marks Sixteen Years of Innovation and Success L2M Discover Radiopharma CPDC Announces Closure of Phase 3 Clinical Trial of [18F]PSMA-1007 Prostate Cancer Diagnostic Imaging Agent CPDC Funds Research at CAMH for Developing Alk2-Targeting Pet Tracer for Diagnosis of Pediatric Brain Cancer Notre objectif CPDC Funds Research at Simon Fraser University for Developing an LAT1-Targeting PET Tracer for Imaging Cancer The Centre For Probe Development And Commercialization and Triumf Innovations to Receive Up To $35 Million in Funding for their Canadian Medical Isotope Ecosystem Lab2Market Partners with CPDC to Launch L2M Discover Radiopharma Program